Bristol Myers Squibb Completes Acquisition Of Turning Point Therapeutics, Expanding Precision Oncology Portfolio
Bristol Myers Squibb Completes Acquisition Of Turning Point Therapeutics, Expanding Precision Oncology Portfolio
08/17/22, 12:33 PM
Location
princeton
Industry
health care
therapeutics
medical
biotechnology
health care
Bristol Myers Squibb (NYSE:BMY) announced today that it has successfully completed its acquisition of Turning Point Therapeutics, Inc. (“Turning Point”), in an all-cash transaction. With the completion of the acquisition, Turning Point shares have ceased trading on the NASDAQ Global Select Market and Turning Point is now a wholly owned subsidiary of Bristol Myers Squibb.
Company Info
Location
Princeton, New Jersey, United States
Company info
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.